UnitedHealth Group reported third-quarter earnings that significantly exceeded analyst expectations and raised its full-year profit outlook, signaling strong operational performance despite ongoing high medical costs [1]. The company now expects fiscal 2026 adjusted earnings of at least $20.50 per share, up from its previous guidance of $19.50 to $20 per share [1]. For the third quarter, UnitedHealth posted adjusted earnings per share of $4.69, surpassing the $4.14 expected by analysts, and reported revenue of $112.69 billion, also above the $111.40 billion consensus estimate [1].
Net income for the quarter reached $4.11 billion, or $4.56 per share, compared to $2.35 billion, or $2.59 per share, in the same period last year [1]. The company's insurer, UnitedHealthcare, and its Optum healthcare unit both exceeded analysts' operating earnings estimates for the quarter [1]. Despite a slight year-over-year decline in revenue from $113.16 billion to $112.69 billion, UnitedHealth's medical cost ratio—a key profitability metric—improved to 88.4%, better than the 89.9% expected by analysts [1]. This lower ratio indicates improved profitability, as the company collected more in premiums than it paid out in benefits [1].
CFO Wayne DeVeydt attributed the strong results to ongoing investments in value-based care and artificial intelligence, as well as strategic actions such as shrinking membership, exiting unprofitable contracts, and focusing on quality and cost-effective care [1]. DeVeydt cautioned, however, that medical costs remain elevated compared to historical norms, particularly in privately run Medicare Advantage plans, and suggested continued vigilance is warranted [1].
Following the earnings report, UnitedHealth shares rose about 3% in premarket trading, reflecting positive market sentiment and investor confidence in the company's turnaround strategy and improved outlook [1].
CONCLUSION
UnitedHealth Group's strong third-quarter performance and raised profit outlook have boosted investor confidence, as evidenced by a 3% rise in premarket shares. The company's focus on value-based care and cost management is yielding results, though elevated medical costs remain a concern. Overall, the market reaction is positive, with expectations for continued operational improvement.